Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

European Respiratory Journal

Volumn 52, Issue 4, 2018, Pages

  Bleecker, Eugene R ^a   Wechsler, Michael E ^b   Mark FitzGerald, J ^c   Menzies Gow, Andrew ^d   Wu, Yanping ^e   Hirsch, Ian ^e   Goldman, Mitchell ^e   Newbold, Paul ^f   Zangrilli, James G ^e  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

^f MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENRALIZUMAB; CORTICOSTEROID; PLACEBO; ANTIASTHMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ASTHMA; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG USE; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NOSE POLYP; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; ADOLESCENT; AGED; CHILD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECT; EOSINOPHIL; LEUKOCYTE COUNT; MIDDLE AGED; PATHOPHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85055156869     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00936-2018     Document Type: Article

References (40)

1. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012; 12: 204.
2. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012; 42: 650–658.
3. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716–725.
4. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.
5. O’Byrne PM, Pedersen S, Schatz M, et al. The poorly explored impact of uncontrolled asthma. Chest 2013; 143: 511–523.
6. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract 2017; 3: 1.
7. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2017. www.ginasthma.org/ 2017-gina-report-global-strategy-for-asthma-management-and-prevention Date last accessed: March 12, 2018.
8. Pavord ID. Eosinophilic phenotypes of airway disease. Ann Am Thorac Soc 2013; 10: Suppl., S143–S149.
9. Price D, Wilson AM, Chisholm A, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy 2016; 9: 1–12.
10. 1 decline in occupational asthma: results of an observational study. BMJ Open 2015; 5: e005748.
11. 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388: 2115–2127.
12. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388: 2128–2141.
13. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198–1207.
14. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651–659.
15. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3: 355–366.
16. Fowler SJ, Tavernier G, Niven R. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. J Allergy Clin Immunol 2015; 135: 822–824.
17. Hastie AT, Moore WC, Li H, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 2013; 132: 72–80.
18. NO and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015; 70: 115–120.
19. Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010; 125: 1344–1353.
20. Pham TH, Damera G, Newbold P, et al. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med 2016; 111: 21–29.
21. Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132: 1086–1096.
22. Sehmi R, Lim HF, Mukherjee M, et al. Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma. J Allergy Clin Immunol 2018; 141: 1529–1532.
23. Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N Engl J Med 2017; 376: 2448–2458.
24. AstraZeneca. Fasenra™ (Benralizumab). Prescribing Information. 2017. www.azpicentral.com/fasenra/fasenra_pi. pdf Date last updated: November, 2017. Date last accessed: January 10, 2018.
25. AstraZeneca. Fasenra™ (Benralizumab). Summary of Product Characteristics. 2018. http://ec.europa.eu/health/documents/community-register/2018/20180108139598/anx_139598_en.pdf Date last accessed: March 13, 2018.
26. FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med 2018; 6: 51–64.
27. Juniper EF, Svensson K, Mork AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99: 553–558.
28. de Groot JC, ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res 2015; 1: 00024-2015.
29. Buhl R, Humbert M, Bjermer L, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J 2017; 49: 1700634.
30. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144–2148.
31. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167: 199–204.
32. Kips JC, O’Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167: 1655–1659.
33. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101: 1483–1492.
34. ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164: 744–748.
35. Inoue H, Ito I, Niimi A, et al. CT-assessed large airway involvement and lung function decline in eosinophilic asthma: the association between induced sputum eosinophil differential counts and airway remodeling. J Asthma 2016; 53: 914–921.
36. Gevaert P, Hellman C, Lundblad L, et al. Differential expression of the interleukin 5 receptor alpha isoforms in blood and tissue eosinophils of nasal polyp patients. Allergy 2009; 64: 725–732.
37. Ediger D, Sin BA, Heper A, et al. Airway inflammation in nasal polyposis: immunopathological aspects of relation to asthma. Clin Exp Allergy 2005; 35: 319–326.
38. Westerhof GA, Coumou H, de Nijs SB, et al. Clinical predictors of remission and persistence of adult-onset asthma. J Allergy Clin Immunol 2018; 141: 104–109.
39. Sorkness RL, Bleecker ER, Busse WW, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008; 104: 394–403.
40. Tanaka A, Uno T, Sato H, et al. Predicting future risk of exacerbations in Japanese patients with adult asthma: a prospective 1-year follow up study. Allergol Int 2017; 66: 568–573.